ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

ReCode Therapeutics (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for pulmonary diseases, today announced the close of an oversubscribed $80 million Series A financing round.